Tyndall Capital Partners’s Onconova Therapeutics, Inc. Warrants ONTXW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-390,624
| Closed | -$14K | – | 2 |
|
|
2019
Q4 | $14K | Hold |
390,624
| – | – | 0.6% | 2 |
|
|
2019
Q3 | $8K | Hold |
390,624
| – | – | 0.3% | 3 |
|
|
2019
Q2 | $70K | Hold |
390,624
| – | – | 1.42% | 3 |
|
|
2019
Q1 | $74K | Hold |
390,624
| – | – | 1.46% | 3 |
|
|
2018
Q4 | $16K | Hold |
390,624
| – | – | 0.45% | 3 |
|
|
2018
Q3 | $39K | Hold |
390,624
| – | – | 0.49% | 3 |
|
|
2018
Q2 | $5K | Hold |
390,624
| – | – | 0.07% | 3 |
|
|
2018
Q1 | $117K | Hold |
390,624
| – | – | 3.05% | 3 |
|
|
2017
Q4 | $215K | Hold |
390,624
| – | – | 6.19% | 3 |
|
|
2017
Q3 | $152K | Hold |
390,624
| – | – | 1.94% | 4 |
|
|
2017
Q2 | $176K | Hold |
390,624
| – | – | 2.08% | 4 |
|
|
2017
Q1 | $327K | Hold |
390,624
| – | – | 9.4% | 3 |
|
|
2016
Q4 | $391K | Hold |
390,624
| – | – | 13.7% | 3 |
|
|
2016
Q3 | $391K | Buy |
+390,624
| New | +$413K | 21.2% | 2 |
|
Tyndall Capital Partners's ONTXW Position: Q1 2020 in Review
Tyndall Capital Partners sold out of Onconova Therapeutics, Inc. Warrants (ONTXW) in Q1 2020, closing a stake of 390,624 shares — an estimated $14K sold.
Tyndall Capital Partners first reported a position in ONTXW in Q3 2016 and held it in 14 quarters. The position peaked at $391K in Q4 2016. 1 fund tracked by Wall St. Rank holds ONTXW as of Q1 2020.
- Tyndall Capital Partners reported no remaining Onconova Therapeutics, Inc. Warrants position as of Q1 2020 after selling out during the quarter.
- Tyndall Capital Partners sold 390,624 Onconova Therapeutics, Inc. Warrants shares in Q1 2020, an estimated $14K.
- Tyndall Capital Partners first reported a position in Onconova Therapeutics, Inc. Warrants in Q3 2016 and held it in 14 quarters.
- Tyndall Capital Partners's Onconova Therapeutics, Inc. Warrants position peaked at $391K in Q4 2016.
- 1 fund tracked by Wall St. Rank held Onconova Therapeutics, Inc. Warrants as of Q1 2020.
Based on Tyndall Capital Partners's 13F filing for Q1 2020.